Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.59 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.59 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.56 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155682 | 1.00 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL18241088 | 0.98 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2862492 | 0.98 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4334091 | 0.93 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27821605 | 0.88 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL2550326 | 0.86 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3401436 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL29676554 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3400330 | 0.85 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL6806463 | 0.84 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | claimed |
| EP-2880046-B1 | NOVEL CHARTREUSIN ANALOGUES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2016-12-21 | — | — | EP | claimed |
| US-9522930-B2 | Chartreusin analogues | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2016-12-20 | — | — | US | claimed |
| US-20150197539-A1 | NOVEL CHARTREUSIN ANALOGUES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2015-07-16 | — | — | US | claimed |
| US-8779138-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2014-07-15 | — | — | US | claimed |
| US-8563537-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2013-10-22 | — | — | US | claimed |
| WO-2012134446-A1 | EPIANDROSTERONE AND/OR ANDROSTERONE DERIVATIVES AND METHOD OF USE THEREOF | SUTTER WEST BAY HOSPITALS doing business as CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2012-10-04 | — | — | WO | claimed |
| CN-101481377-B | Chemical semisynthesis process of irinotecan | SHANGHAI LONGXIANG BIOLOG MEDICINE DEV CO LTD | 2012-08-15 | — | — | CN | claimed |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2011-07-28 | — | — | US | claimed |
| US-7875602-B2 | Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in cancer treatment in combination with radiotherapy; less toxic | SUTTER WEST BAY HOSPITALS (US) | 2011-01-25 | — | — | US | claimed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | claimed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | claimed |
| EP-1383772-B1 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2006-08-30 | — | — | EP | claimed |
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ALANINE ALEXANDER | 2006-01-05 | — | — | US | claimed |
| US-6933302-B2 | Nitrogen-based homo-camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-08-23 | — | — | US | claimed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | claimed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | claimed |
| US-20040034050-A1 | Homo-camptothecin derivatives | CATHOLIC HEALTHCARE WEST, DOING BUSINESS AS ST. MARY'S MEDICAL CENTER OF SAN FRANCISCO | 2004-02-19 | — | — | US | claimed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | claimed |
| WO-2003101406-A1 | HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003986-A1 | Benzothiazole derivatives with activity as adenosine receptor ligands | ADORA2A, ADORA1, ADORA3 | L3MBTL3 4286/4885L3MBTL1 3541/4885MBTD1 460/4885 |
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | L3MBTL3 3261/4885L3MBTL1 3543/4885MBTD1 4452/4885 |
| US-20150197539-A1 | NOVEL CHARTREUSIN ANALOGUES | CYP17A1, CYP27A1, CYP46A1 | L3MBTL3 4777/4885L3MBTL1 4759/4885MBTD1 2713/4885 |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | ERCC2, CHEK1, ERCC4 | L3MBTL3 1559/4885L3MBTL1 1052/4885MBTD1 902/4885 |
| US-20040034050-A1 | Homo-camptothecin derivatives | CYP8B1, HCAR3, MTHFD2 | L3MBTL3 1180/4885L3MBTL1 830/4885MBTD1 3047/4885 |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | ERCC2, CHEK1, ERCC4 | L3MBTL3 1559/4885L3MBTL1 1052/4885MBTD1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.